AMLX Form 4: Chief Legal Officer Sells 8,828 Shares at $14.58

Gina Mazzariello, Chief Legal Officer of Amylyx Pharmaceuticals, Inc. (AMLX), reported the automatic sale of 8,828 shares of common stock to satisfy tax withholding related to the vesting of restricted stock units.

Rhea-AI Filing Summary

Gina Mazzariello, Chief Legal Officer of Amylyx Pharmaceuticals, Inc. (AMLX), reported the automatic sale of 8,828 shares of common stock to satisfy tax withholding related to the vesting of restricted stock units. The weighted average price reported for the sales was $14.5751, with execution prices ranging from $14.355 to $15.075. After the transaction, the filing shows the reporting person beneficially owns 148,141 shares. The filing notes the sales were automatic to cover tax obligations and not at the reporting person's discretion.

Insider Trade Summary

Net Seller: 8,828 shares

Net Sell 1 txn

Insider Mazzariello Gina

Role Chief Legal Officer

Sold 8,828 shs ($129K)

Type	Security	Shares	Price	Value
Sale	Common Stock	8,828	$14.5751	$129K

Holdings After Transaction: Common Stock — 148,141 shares (Direct)

Footnotes (2)

1. F1. Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person.
2. F2. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $14.355 to $15.075. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What transaction did Gina Mazzariello report on Form 4 for AMLX?

The Form 4 reports the automatic sale of 8,828 shares to cover tax withholding from vested restricted stock units.

At what price were the AMLX shares sold in the reported transaction?

The filing reports a weighted average sale price of $14.5751, with individual sale prices ranging from $14.355 to $15.075.

How many AMLX shares does the reporting person beneficially own after the sale?

The filing shows beneficial ownership of 148,141 shares following the reported transaction.

Why were the AMLX shares sold according to the Form 4?

The filing states the shares were sold automatically to satisfy tax withholding obligations arising from the vesting of restricted stock units, and the sales were not at the reporting person's discretion.

What role does the reporting person hold at AMLX?

The reporting person, Gina Mazzariello, is listed as the company's Chief Legal Officer.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 10/02/2025 - 04:15 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Mazzariello Gina

(Last) (First) (Middle)

C/O AMYLYX PHARMACEUTICALS, INC.

43 THORNDIKE STREET

(Street)

CAMBRIDGE MA 02141

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Amylyx Pharmaceuticals, Inc. [ AMLX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Legal Officer

3. Date of Earliest Transaction (Month/Day/Year)
09/30/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/30/2025		S(1)		8,828(1)	D	$14.5751(2)	148,141	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person.

2. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $14.355 to $15.075. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

	/s/ Joshua B. Cohen, as Attorney in Fact	10/02/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.